At Imago BioSciences, the science leads us to achieving the greatest patient benefit. While drug development rarely takes a straight path – it’s often marked by twists and turns – following the science is the only way to successfully find new treatments for malignant, life-threatening diseases of the bone marrow.
(noun) 1. The final and fully developed stage of an insect after its metamorphosis.
In this process of growth and development, the imago stage refers to the fully formed adult – one that has completed its transformation. In our view, the full maturation of a scientific idea or observation in medical research is when new treatments clinically prove their worth to patients. Anything less misses the mark.
With a new approach to treating malignant, life-threatening diseases of the bone marrow, our team follows the data to find the right applications of our drugs for patients.
Patients with essential thrombocythemia and myelofibrosis need new, safe and effective options. Our pipeline of therapies reflects our aim to address this immense need.
We see promise for patients through the lens of science. We’re evaluating our lead therapeutic candidate – bomedemstat – in clinical trials with the hope of providing a new potential treatment option.
The latest from Imago BioSciences
SOUTH SAN FRANCISCO, Calif. – June 11, 2021 – Imago BioSciences, Inc. (“Imago”), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today provided updates on two Phase 2 clinical trials
SOUTH SAN FRANCISCO, Calif. — June 3, 2021 –(BUSINESS WIRE)– Imago BioSciences, Inc. (“Imago”), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced the appointment of Wan-Jen Hong, M.D., as chief medical officer.
South San Francisco, CA, May 21, 2021 — Imago BioSciences, Inc. (“Imago”), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced that updated Phase 2 data from its two clinical programs
South San Francisco, Calif. – Feb. 9, 2021 – Imago BioSciences, Inc. (Imago), a clinical stage biopharmaceutical company developing innovative treatments for myeloid diseases, today announced that